In the latest trading session,, 0.37 million Akebia Therapeutics Inc (NASDAQ:AKBA) shares changed hands as the company’s beta touched 0.78. With the company’s most recent per share price at $2.62 changing hands around $0.01 or 0.19% at last look, the market valuation stands at $686.79M. AKBA’s current price is a discount, trading about -10.69% off its 52-week high of $2.90. The share price had its 52-week low at $0.80, which suggests the last value was 69.47% up since then.
Analysts gave the Akebia Therapeutics Inc (AKBA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKBA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Akebia Therapeutics Inc’s EPS for the current quarter is expected to be -0.04.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA is in green as seen in intraday trades today. With action 7.61%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 37.63%, with the 5-day performance at 7.61% in the green. However, in the 30-day time frame, Akebia Therapeutics Inc (NASDAQ:AKBA) is 26.94% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 59.69% from its recent market value. According to analyst projections, AKBA’s forecast low is 6 with 7 as the target high. To hit the forecast high, the stock’s price needs a -167.18% plunge from its current level, while the stock would need to soar -129.01% for it to hit the projected low.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
Year-over-year growth is forecast to reach 23.99% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 47.15M. 5 analysts are of the opinion that Akebia Therapeutics Inc’s revenue for the current quarter will be 43.88M. The company’s revenue for the corresponding quarters a year ago was 43.65M and 37.43M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 8.03%. The estimates for the next quarter sales put growth at 17.23%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.58%. The 2025 estimates are for Akebia Therapeutics Inc earnings to increase by 68.48%.
AKBA Dividends
Akebia Therapeutics Inc is expected to release its next quarterly earnings report in June.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.4235% or 9.28 million shares worth $9.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 5.95 shares estimated at $15.64 million under it, the former controlled 2.26% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.21% of the shares, roughly 5.79 shares worth around $15.24 million.
